LMO2 is an intrinsically disordered transcription factor activated in T cell leukaemia that is difficult to target. It forms part of a multiprotein complex that has bipartite DNA binding through ...

Researchers at Fred Hutch Cancer Center invented a new screening method called ReLiC that uses CRISPR-Cas9 to test all the ...